Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects

Simona Volpi; Carol J. Bult; Rex L. Chisholm; Patricia A. Deverka; Geoffrey S. Ginsburg; Howard J. Jacob; Melpomeni Kasapi; Howard L. McLeod; Dan M. Roden; Marc S. Williams; Eric D. Green; Laura Lyman Rodriguez; Samuel Aronson; Larisa H. Cavallari; Joshua C. Denny; Lynn G. Dressler; Julie A. Johnson; Teri E. Klein; J. Steven Leeder; Micheline Piquette-Miller; Minoli Perera; Laura J. Rasmussen-Torvik; Heidi L. Rehm; Marylyn D. Ritchie; Todd C. Skaar; Nikhil Wagle; Richard Weinshilboum; Kristin W. Weitzel; Robert Wildin; John Wilson; Teri A. Manolio; Mary V. Relling

doi:10.1002/cpt.1048

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects

Simona Volpi^*, Carol J. Bult, Rex L. Chisholm, Patricia A. Deverka, Geoffrey S. Ginsburg, Howard J. Jacob, Melpomeni Kasapi, Howard L. McLeod, Dan M. Roden, Marc S. Williams, Eric D. Green, Laura Lyman Rodriguez, Samuel Aronson, Larisa H. Cavallari, Joshua C. Denny, Lynn G. Dressler, Julie A. Johnson, Teri E. Klein, J. Steven Leeder, Micheline Piquette-MillerMinoli Perera, Laura J. Rasmussen-Torvik, Heidi L. Rehm, Marylyn D. Ritchie, Todd C. Skaar, Nikhil Wagle, Richard Weinshilboum, Kristin W. Weitzel, Robert Wildin, John Wilson, Teri A. Manolio, Mary V. Relling

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

98 Scopus citations

Abstract

Response to a drug often differs widely among individual patients. This variability is frequently observed not only with respect to effective responses but also with adverse drug reactions. Matching patients to the drugs that are most likely to be effective and least likely to cause harm is the goal of effective therapeutics. Pharmacogenomics (PGx) holds the promise of precision medicine through elucidating the genetic determinants responsible for pharmacological outcomes and using them to guide drug selection and dosing. Here we survey the US landscape of research programs in PGx implementation, review current advances and clinical applications of PGx, summarize the obstacles that have hindered PGx implementation, and identify the critical knowledge gaps and possible studies needed to help to address them.

Original language	English (US)
Pages (from-to)	778-786
Number of pages	9
Journal	Clinical pharmacology and therapeutics
Volume	103
Issue number	5
DOIs	https://doi.org/10.1002/cpt.1048
State	Published - May 2018

Funding

The May 2017 symposium convened by the National Human Genome Research Institute (NHGRI) was funded by the NIH U01HG007282 grant. As an Associate Editor for Clinical Pharmacology & Therapeutics, Micheline Piquette-Miller was not involved in the review or decision process for this paper.

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1002/cpt.1048

Cite this

Volpi, S., Bult, C. J., Chisholm, R. L., Deverka, P. A., Ginsburg, G. S., Jacob, H. J., Kasapi, M., McLeod, H. L., Roden, D. M., Williams, M. S., Green, E. D., Rodriguez, L. L., Aronson, S., Cavallari, L. H., Denny, J. C., Dressler, L. G., Johnson, J. A., Klein, T. E., Leeder, J. S., ... Relling, M. V. (2018). Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. Clinical pharmacology and therapeutics, 103(5), 778-786. https://doi.org/10.1002/cpt.1048

@article{2920cf26134a440495fa7cc742730024,

title = "Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects",

abstract = "Response to a drug often differs widely among individual patients. This variability is frequently observed not only with respect to effective responses but also with adverse drug reactions. Matching patients to the drugs that are most likely to be effective and least likely to cause harm is the goal of effective therapeutics. Pharmacogenomics (PGx) holds the promise of precision medicine through elucidating the genetic determinants responsible for pharmacological outcomes and using them to guide drug selection and dosing. Here we survey the US landscape of research programs in PGx implementation, review current advances and clinical applications of PGx, summarize the obstacles that have hindered PGx implementation, and identify the critical knowledge gaps and possible studies needed to help to address them.",

author = "Simona Volpi and Bult, {Carol J.} and Chisholm, {Rex L.} and Deverka, {Patricia A.} and Ginsburg, {Geoffrey S.} and Jacob, {Howard J.} and Melpomeni Kasapi and McLeod, {Howard L.} and Roden, {Dan M.} and Williams, {Marc S.} and Green, {Eric D.} and Rodriguez, {Laura Lyman} and Samuel Aronson and Cavallari, {Larisa H.} and Denny, {Joshua C.} and Dressler, {Lynn G.} and Johnson, {Julie A.} and Klein, {Teri E.} and Leeder, {J. Steven} and Micheline Piquette-Miller and Minoli Perera and Rasmussen-Torvik, {Laura J.} and Rehm, {Heidi L.} and Ritchie, {Marylyn D.} and Skaar, {Todd C.} and Nikhil Wagle and Richard Weinshilboum and Weitzel, {Kristin W.} and Robert Wildin and John Wilson and Manolio, {Teri A.} and Relling, {Mary V.}",

note = "Publisher Copyright: {\textcopyright} 2018 American Society for Clinical Pharmacology and Therapeutics",

year = "2018",

month = may,

doi = "10.1002/cpt.1048",

language = "English (US)",

volume = "103",

pages = "778--786",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "5",

}

Volpi, S, Bult, CJ, Chisholm, RL, Deverka, PA, Ginsburg, GS, Jacob, HJ, Kasapi, M, McLeod, HL, Roden, DM, Williams, MS, Green, ED, Rodriguez, LL, Aronson, S, Cavallari, LH, Denny, JC, Dressler, LG, Johnson, JA, Klein, TE, Leeder, JS, Piquette-Miller, M, Perera, M , Rasmussen-Torvik, LJ, Rehm, HL, Ritchie, MD, Skaar, TC, Wagle, N, Weinshilboum, R, Weitzel, KW, Wildin, R, Wilson, J, Manolio, TA & Relling, MV 2018, 'Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects', Clinical pharmacology and therapeutics, vol. 103, no. 5, pp. 778-786. https://doi.org/10.1002/cpt.1048

TY - JOUR

T1 - Research Directions in the Clinical Implementation of Pharmacogenomics

T2 - An Overview of US Programs and Projects

AU - Volpi, Simona

AU - Bult, Carol J.

AU - Chisholm, Rex L.

AU - Deverka, Patricia A.

AU - Ginsburg, Geoffrey S.

AU - Jacob, Howard J.

AU - Kasapi, Melpomeni

AU - McLeod, Howard L.

AU - Roden, Dan M.

AU - Williams, Marc S.

AU - Green, Eric D.

AU - Rodriguez, Laura Lyman

AU - Aronson, Samuel

AU - Cavallari, Larisa H.

AU - Denny, Joshua C.

AU - Dressler, Lynn G.

AU - Johnson, Julie A.

AU - Klein, Teri E.

AU - Leeder, J. Steven

AU - Piquette-Miller, Micheline

AU - Perera, Minoli

AU - Rasmussen-Torvik, Laura J.

AU - Rehm, Heidi L.

AU - Ritchie, Marylyn D.

AU - Skaar, Todd C.

AU - Wagle, Nikhil

AU - Weinshilboum, Richard

AU - Weitzel, Kristin W.

AU - Wildin, Robert

AU - Wilson, John

AU - Manolio, Teri A.

AU - Relling, Mary V.

PY - 2018/5

Y1 - 2018/5

N2 - Response to a drug often differs widely among individual patients. This variability is frequently observed not only with respect to effective responses but also with adverse drug reactions. Matching patients to the drugs that are most likely to be effective and least likely to cause harm is the goal of effective therapeutics. Pharmacogenomics (PGx) holds the promise of precision medicine through elucidating the genetic determinants responsible for pharmacological outcomes and using them to guide drug selection and dosing. Here we survey the US landscape of research programs in PGx implementation, review current advances and clinical applications of PGx, summarize the obstacles that have hindered PGx implementation, and identify the critical knowledge gaps and possible studies needed to help to address them.

AB - Response to a drug often differs widely among individual patients. This variability is frequently observed not only with respect to effective responses but also with adverse drug reactions. Matching patients to the drugs that are most likely to be effective and least likely to cause harm is the goal of effective therapeutics. Pharmacogenomics (PGx) holds the promise of precision medicine through elucidating the genetic determinants responsible for pharmacological outcomes and using them to guide drug selection and dosing. Here we survey the US landscape of research programs in PGx implementation, review current advances and clinical applications of PGx, summarize the obstacles that have hindered PGx implementation, and identify the critical knowledge gaps and possible studies needed to help to address them.

UR - http://www.scopus.com/inward/record.url?scp=85044524491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044524491&partnerID=8YFLogxK

U2 - 10.1002/cpt.1048

DO - 10.1002/cpt.1048

M3 - Article

C2 - 29460415

AN - SCOPUS:85044524491

SN - 0009-9236

VL - 103

SP - 778

EP - 786

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 5

ER -

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this